Evidence map›Paper›PMID 36681790›Full record

ArticleBMC public health2023

Bioinformatic modelling of SARS-CoV-2 pandemic with a focus on country-specific dynamics.

Jakub Liu, Tomasz Suchocki, Joanna Szyda

Abstract read
In one paragraph

Article in BMC public health, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Jakub LiuBiostatistics Group, Department of Genetics, Wroclaw University of Environmental and Life Sciences, Kozuchowska 7, 51-631, Wroclaw, Poland.
Tomasz SuchockiBiostatistics Group, Department of Genetics, Wroclaw University of Environmental and Life Sciences, Kozuchowska 7, 51-631, Wroclaw, Poland.
Joanna SzydaBiostatistics Group, Department of Genetics, Wroclaw University of Environmental and Life Sciences, Kozuchowska 7, 51-631, Wroclaw, Poland. joanna.szyda@upwr.edu.pl.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOne of the seminal events since 2019 has been the outbreak of the SARS-CoV-2 pandemic. Countries have adopted various policies to deal with it, but they also differ in their socio-geographical characteristics and public health care facilities. Our study aimed to investigate differences between epidemiological parameters across countries.

methodThe analysed data represents SARS-CoV-2 repository provided by the Johns Hopkins University. Separately for each country, we estimated recovery and mortality rates using the SIRD model applied to the first 30, 60, 150, and 300 days of the pandemic. Moreover, a mixture of normal distributions was fitted to the number of confirmed cases and deaths during the first 300 days. The estimates of peaks' means and variances were used to identify countries with outlying parameters.

resultsFor 300 days Belgium, Cyprus, France, the Netherlands, Serbia, and the UK were classified as outliers by all three outlier detection methods. Yemen was classified as an outlier for each of the four considered timeframes, due to high mortality rates. During the first 300 days of the pandemic, the majority of countries underwent three peaks in the number of confirmed cases, except Australia and Kazakhstan with two peaks.

conclusionsConsidering recovery and mortality rates we observed heterogeneity between countries. Liechtenstein was the "positive" outlier with low mortality rates and high recovery rates, at the opposite, Yemen represented a "negative" outlier with high mortality for all four considered periods and low recovery for 30 and 60 days.

Indexed as

COVID-19SARS-CoV-2Disease OutbreaksFranceHumansPandemicsCOVID-19Mixture modelOutlierSIRD

Identifiers

PMID36681790
PMCPMC9862223

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.